Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer

  • Technology appraisal guidance
  • TA310
  • Published: 

Review decision – June 2018

Decision to transfer to the ‘static guidance list’

The Institute was proposing that this guidance should be transferred to the ‘static guidance list’.

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, TA258 and TA192 will remain on the ‘static list’, and TA310 should be transferred to the ‘static guidance list’. All 3 topics can then be incorporated into the forthcoming clinical guideline for the diagnosis and management of lung cancer.

Review decision paper

This page was last updated: